Pharmaceutical Packaging Editorial
-
Pastries And Process: A Recipe for Innovation At CDMOs
11/27/2017
Hard truths offset by soft skills make up the outsourced drug development and manufacturing industry. Here are some of those truths, skills, and their syntheses for innovation at CDMOs, from some accomplished biopharma professionals.
-
Two Strategies For Getting Your CMO To Really Listen
10/11/2017
“When you select a vendor and agree to a contract, your roles are now somewhat reversed. You were the boss before you handed out the contract, but the minute the contract is done, you lose the leverage you had. How can you maintain more control?” Here are two strategies from biotech and pharma executives.
-
Less Cost And More Control Limits Supply Chain Success
8/18/2017
Our industry would benefit from the sourcing function focusing less on narrow cost reductions, and more on broader corporate objectives; and from drug owners who allow external partners more control of their own environments. These would add up to a better functioning supply chain, and improved overall business outcomes.
-
Platform Or Perish: 9 Steps To Better Partnerships
7/28/2017
Companies in every industry are defining their next generation of value chains. In doing so, they are increasingly integrating with third parties, and their platforms. Savvy leaders leverage these relationships to unlock their next waves of strategic growth. Here are 9 steps to move the process forward, based on a new report from Accenture.
-
Channeling Socrates With The FDA On Innovative Technologies
7/5/2017
Paraphrasing Henry Hoppe of Xenetic Bioscience, companies on the bleeding edge of innovative technology in drug development and manufacturing should treat visits to the FDA more like Socratic dialogues than stressful duels. Mark Butchko, who’s charted over a decade with Lilly, advises holding some of those dialogues during “pre-operational visits,” or POVs.
-
New Board Members: Co-Creating, Energized, And Positively Provocative
6/28/2017
It’s halftime on 2017. Summer has officially arrived. Can you believe it? A perfect time to … add veteran industry professionals to our organization. Outsourced Pharma is pleased to announce three new Editorial Advisory Board members, from Merck, Eli Lilly, and Tunnell Consulting. Read what they have to say about our industry to this point, and our future.
-
Japan And The Art Of Supply-Chain Specialization
6/12/2017
So you say you’re a specialist. And that’s probably a good thing. But consider this paradox: The best “specialists” are also solid “generalists.” I’m reminded of this contrarian concept by a recent visit to Japan, where I originally learned it, and the ongoing debate at Outsourced Pharma conferences regarding partnerships in the external supply chain.
-
What Is Supply Chain Capacity In 2017?
6/5/2017
“Capacity” for outsourcing development and manufacturing has mostly been defined by a strict calculation of how much material a facility (or facilities) can output over a period of time. Executives from companies like MedImmune and Merck tell us why, unfortunately, that definition doesn’t work anymore.
-
Instant Innovation In The Supply Chain
6/1/2017
In our second part on supply chain innovation, executives at Biogen and Merck discuss the drug industry’s engagement with “instant innovation,” and a bottom up approach to cultural change.
-
Adversity On The Path to Global Drug Distribution
3/3/2017
Not all Outsourced Pharma readers will have had experiences as pronounced as Jennifer Dent’s. But her narrative can spur us to take a look at our own personal – and organizational – missions within the greater biotech and pharma realm, and point to another area where outsourcing drug development and manufacturing professionals can step up our global leadership.